Holen Sie sich die Stockscreener-App
378.89
0.11%
-0.40
Handel nachbörslich:
378.89
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$379.29
Offen:
$369.835
24-Stunden-Volumen:
731.36K
Relative Volume:
0.71
Marktkapitalisierung:
$37.20B
Einnahmen:
$3.77B
Nettoeinkommen (Verlust:
$449.25M
KGV:
48.23
EPS:
7.8556
Netto-Cashflow:
$240.68M
1W Leistung:
+2.72%
1M Leistung:
+3.70%
6M Leistung:
-5.41%
1J Leistung:
+8.19%
1-Tages-Spanne:
$369.45
$380.35
1-Wochen-Bereich:
$364.44
$382.35
52-Wochen-Spanne:
$275.05
$414.15
Waters Corp Stock (WAT) Company Profile
Firmenname
Waters Corp
Sektor
Branche
Telefon
(508) 478-2000
Adresse
34 MAPLE ST, MILFORD, MA
Compare WAT vs TMO, DHR, IDXX, NTRA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
WAT
Waters Corp
|
378.89 | 36.82B | 3.77B | 449.25M | 240.68M | 7.8556 |
TMO
Thermo Fisher Scientific Inc
|
517.60 | 186.32B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
193.62 | 134.82B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
564.98 | 41.53B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
283.80 | 38.88B | 2.50B | -226.32M | 71.51M | -1.6412 |
Waters Corp Stock (WAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2026-02-10 | Fortgesetzt | Barclays | Overweight |
| 2026-02-10 | Fortgesetzt | Citigroup | Buy |
| 2026-02-10 | Fortgesetzt | Evercore ISI | In-line |
| 2026-01-06 | Eingeleitet | Guggenheim | Buy |
| 2026-01-05 | Eingeleitet | William Blair | Outperform |
| 2025-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2025-10-08 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-03-31 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-03-26 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-02-13 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-02-10 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-08 | Hochstufung | Jefferies | Hold → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2023-11-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-31 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-07-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-07-20 | Eingeleitet | UBS | Neutral |
| 2022-05-18 | Eingeleitet | Barclays | Overweight |
| 2022-05-17 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-04-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-07-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-01-07 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-12-17 | Hochstufung | Cleveland Research | Underperform → Buy |
| 2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Neutral |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-07-28 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-07-16 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-01-08 | Herabstufung | Needham | Hold → Underperform |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Eingeleitet | Citigroup | Sell |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-10-09 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2019-07-16 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-06-12 | Herabstufung | Cleveland Research | Neutral → Underperform |
| 2019-05-30 | Eingeleitet | Wolfe Research | Underperform |
| 2019-01-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-01-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-01-03 | Eingeleitet | Needham | Hold |
| 2018-12-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-11-30 | Herabstufung | Goldman | Neutral → Sell |
| 2018-10-11 | Hochstufung | Cleveland Research | Sell → Neutral |
Alle ansehen
Waters Corp Aktie (WAT) Neueste Nachrichten
Waters Corporation highlights analytical science role amid steady industry demand - AD HOC NEWS
Waters Corp. stock outperforms competitors on strong trading day - MarketWatch
Waters Corp. stock underperforms Monday when compared to competitors - MarketWatch
Waters Corporation with a clear analyst view, shares trade steadily on the NYSE - AD HOC NEWS
ACQUITY Premier System from Waters Corpmetal free flow path for tougher separations - AD HOC NEWS
Waters Corp (WAT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bernstein SocGen resumes Waters stock coverage with outperform rating - Investing.com UK
Waters (WAT) Receives Outperform Rating with $435 Target from Be - GuruFocus
Bernstein SocGen resumes Waters stock coverage with outperform rating By Investing.com - Investing.com Australia
WAT Reinstated by Bernstein -- Rating Upgraded to Outperform - GuruFocus
Waters Corporation clears a fresh analyst mark, shares trade higher on Xetra and NYSE - AD HOC NEWS
Form 4 Waters Corporation For: 25 June By Investing.com - Investing.com Australia
Waters (NYSE: WAT) SVP has 189 shares withheld to cover RSU tax - Stock Titan
Waters Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
SNT Biotech Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients - StreetInsider
Waters, IMU Biosciences partner to accelerate AI immune mapping for precision medicineVietnam Investment Review - Vietnam Investment Review - VIR
Waters Corp (WAT) Stock Up 3.4% and Still Undervalued -- GF Scor - GuruFocus
Waters Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Global Laboratory Equipment Services Market Size/Share Worth USD 62.83 Billion by 2035 at a 8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
IMU Biosciences, Waters form AI immunology partnership - Investing.com
Waters backs IMU’s AI blood test platform for cancer and other diseases - Stock Titan
Waters Corporation (WAT): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Waters Corp (WAT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Waters Corp (WAT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Waters opens the week with earnings focus, shares on NYSE - AD HOC NEWS
Waters Corporation stock: Is WAT underperforming the health care sector? - MSN
Xevo TQ-XS Mass Spectrometer from Waters Corphighly sensitive LC-MS/MS for demanding labs - AD HOC NEWS
Waters StockSunday background on lab-analytics specialist - Ad-hoc-news.de
Precision workflows in the lab, Waters Xevo TQ Absolute quietly pushes LC-MS sensitivity - AD HOC NEWS
Smart workflows at the bench, Waters ACQUITY Arc Bio helps labs keep up - AD HOC NEWS
Subtle but forensic, Waters ACQUITY Premier UHPLC targets stubborn metals - AD HOC NEWS
Waters Corp (WAT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Waters Corp (WAT) Institutional Confidence - TradingKey
Waters Corp (WAT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Waters Corp (WAT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Waters Corp (WAT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Waters Corp (WAT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Waters Corporation Stock: Is WAT Underperforming the Health Care Sector? - Barchart.com
Waters Corp (NYSE:WAT) Technical Setup Signals High-Quality Breakout Opportunity - ChartMill
Waters Arc Premier System targets demanding labs with precision and uptime gains - AD HOC NEWS
Waters Corporation Stock (US9418481035): New product launches keep the stock in focus - Ad-hoc-news.de
Battery safety testing gets a sharper edge with Waters' Coin Cell DSC - AD HOC NEWS
Meridiem Capital Partners LP's Waters Corp(WAT) Holding History - GuruFocus
Waters Corporation Stock (US9418481035): Fundamentals and valuation under the microscope - Ad-hoc-news.de
Waters Launches New Tools As Investors Weigh Biologics And Battery Upside - Yahoo Finance
Waters Corp. stock outperforms competitors despite losses on the day - MarketWatch
Waters Corporation ACQUITY Premier System: UHPLC workhorse for demanding labs - AD HOC NEWS
Calvert U.S. Mid Cap Core Responsible Index Fund's Waters Corp(WAT) Holding History - GuruFocus
Abraham Fortress Fund's Waters Corp(WAT) Holding History - GuruFocus
Westchester Capital Management, Inc.'s Waters Corp(WAT) Holding History - GuruFocus
Waters targets earlier thermal runaway detection with whole-cell coin cell differential scanning calorimeter - R&D World
Finanzdaten der Waters Corp-Aktie (WAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Waters Corp-Aktie (WAT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| FEARON RICHARD H | Director |
Mar 06 '26 |
Buy |
306.34 |
1,000 |
306,340 |
3,302 |
| KUEBLER CHRISTOPHER A | Director |
Nov 05 '25 |
Option Exercise |
130.35 |
3,761 |
490,246 |
18,796 |
0.07%
1.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):